Apeiron Presight Capital Fund II, L.P. 4
4 · Alto Neuroscience, Inc. · Filed Mar 6, 2024
Insider Transaction Report
Form 4
Apeiron Investment Group Ltd.
10% Owner
Transactions
- Conversion
Common Stock
2024-02-06+674,658→ 674,658 total(indirect: By Apeiron Presight Capital Fund II, L.P.() - Conversion
Series A Preferred Stock
2024-02-06−1,063,918→ 0 total(indirect: By Apeiron Presight Capital Fund II, L.P.)→ Common Stock (478,359 underlying) - Conversion
Common Stock
2024-02-06+251,881→ 251,881 total - Conversion
Series A Preferred Stock
2024-02-06−406,072→ 0 total→ Common Stock (182,577 underlying) - Conversion
Series B Preferred Stock
2024-02-06−416,665→ 0 total(indirect: By Apeiron Presight Capital Fund II, L.P.)→ Common Stock (196,299 underlying) - Conversion
Warrants to Purchase Series A Preferred Stock
2024-02-06−444,561→ 0 total→ Common Stock (69,304 underlying)
Footnotes (5)
- [F1]In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.
- [F2]The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.
- [F3]The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.
- [F4]In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis.
- [F5]In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis.